Angiotech appoints Victor Diaz as Senior Vice President, Global Manufacturing & Supply Chain Management

    VANCOUVER, March 7 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:   ANPI,
TSX: ANP), a global specialty pharmaceutical and medical device company, today
announced the appointment of Victor Diaz as Senior Vice President, Global
Manufacturing & Supply Chain Management.
    "With his significant accomplishments in manufacturing and supply chain
operations in health care and the medical device industries, we are pleased to
welcome Victor to Angiotech's senior management team," said Dr. William
Hunter, President and CEO of Angiotech.
    Mr. Diaz has over 20 years experience in the health care, medical device,
and medical instruments industries. He brings to Angiotech a solid background
in global manufacturing, Six Sigma, procurement, distribution, supply chain,
lean manufacturing, inventory management, ISO and FDA regulations and
    "As we anticipate more growth in the future, we believe that Victor will
lend his experience to align Angiotech's people and manufacturing resources,
build out our supply chain strategy, develop best practices across all of our
facilities, and increase manufacturing and operational productivity," added
Dr. Hunter.
    Prior to joining Angiotech, Mr. Diaz was Vice President, Global
Operations at Teleflex Medical, the medical device and instrument
manufacturing division of Teleflex Corporation. During his career at Teleflex,
Mr. Diaz led a staff of 4,200 people and was responsible for the global
manufacturing, procurement, distribution and complete supply chain with 25
plants and 23 distribution centers in 10 countries in Europe, Asia, Latin
America and the U.S. Mr. Diaz also spent three years at Tyco Healthcare
Respiratory where he was Vice President of Manufacturing, responsible for 11
manufacturing facilities in 5 countries in Europe, Mexico, and the U.S. Prior
to joining Tyco Respiratory, Mr. Diaz was Vice President of Manufacturing for
Kendall Healthcare, a subsidiary of Tyco Healthcare that manufactured
disposable medical products, where he was responsible for 4,000 employees at
FDA compliant ISO and EN certified plants in Europe, Mexico, Venezuela,
Malaysia, Thailand and the U.S.

    Note on Forward Looking Statements:

    Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimate," "continue," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. All such statements are made
pursuant to the "safe harbor" provisions of applicable securities legislation.
Such forward-looking statements involve known and unknown risks, uncertainties
and other factors that may cause the actual results, events or developments to
be materially different from any future results, events or developments
expressed or implied by such forward-looking statements. Many such risks,
uncertainties and other factors are taken into account as part of our
assumptions underlying these forward-looking statements and include, among
others, the following; general economic and business conditions, both
nationally and in the regions in which we operate; market demand;
technological changes that could impact our existing products or our ability
to develop and commercialize future products; competition; existing
governmental regulations and changes in, or the failure to comply with,
governmental regulations; decisions, and the timing of decisions, made by
health regulatory agencies regarding approval of our technology and products;
the requirement for substantial funding to conduct research and development
and to expand commercialization activities; and any other factors that may
affect performance. In addition, our business is subject to certain operating
risks that may cause the actual results expressed or implied by the
forward-looking statements in this report to differ materially from our actual
results. These operating risks include; poor performance of the product in the
clinical setting; adverse events related to the use of the product; improper
estimation of the size of the wound closure market in the U.S.; adverse
results or unexpected delays in clinical development processes; our ability to
attract and retain qualified personnel; our ability to successfully complete
preclinical and clinical development of our products; changes in business
strategy or development plans; our failure to obtain patent protection for
discoveries; loss of patent protection resulting from third party challenges
to our patents; commercialization limitations imposed by patents owned or
controlled by third parties; our ability to obtain rights to technology from
licensors; liability for patent claims and other claims asserted against us;
our ability to obtain and enforce timely patent and other intellectual
property protection for our technology and products; the ability to enter
into, and to maintain, corporate alliances relating to the development and
commercialization of our technology and products; market acceptance of our
technology and products; our ability to successfully manufacture, market and
sell our products; the continued availability of capital to finance our
activities; our ability to continue to integrate into our business the
operations of American Medical Instruments Holdings, Inc. and our ability to
achieve the operational and other synergies and the other commercial or
financial benefits expected as a result of that acquisition; and any other
factors referenced in our annual information form and other filings with the
applicable Canadian securities regulatory authorities or the SEC.
    Given these uncertainties, assumptions and risk factors, readers are
cautioned not to place undue reliance on such forward-looking statements. We
disclaim any obligation to update any such factors or to publicly announce the
result of any revisions to any of the forward-looking statements contained in
this prospectus to reflect future results, events or developments.

    About Angiotech

    Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with 17 facilities in 6 countries and over 1,500
dedicated employees. Angiotech discovers, develops and markets innovative
treatment solutions for diseases or complications associated with medical
device implants, surgical interventions and acute injury. To find out more
about Angiotech (NASDAQ:   ANPI, TSX: ANP), please visit our website at

For further information:

For further information: Janet Craig, VP, Investor Relations and
Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 221-6933,; Jodi Regts, Manager, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7930,

Organization Profile

Angiotech Pharmaceuticals, Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890